1715 related articles for article (PubMed ID: 30835255)
1. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
2. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
3. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
4. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
5. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
[TBL] [Abstract][Full Text] [Related]
6. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
7. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
Chen X; Yang J; Wang L; Liu B
Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
[TBL] [Abstract][Full Text] [Related]
8. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
[TBL] [Abstract][Full Text] [Related]
9. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
[TBL] [Abstract][Full Text] [Related]
10. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
[TBL] [Abstract][Full Text] [Related]
11. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
[TBL] [Abstract][Full Text] [Related]
12. Personalized cancer neoantigen vaccines come of age.
Chu Y; Liu Q; Wei J; Liu B
Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
[TBL] [Abstract][Full Text] [Related]
13. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomic Platform for Identification of Tumor Specific Antigens.
Faktor J; Hernychová L; Vojtěšek B; Hupp T
Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
[TBL] [Abstract][Full Text] [Related]
15. Cancer neoantigen: Boosting immunotherapy.
Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
[TBL] [Abstract][Full Text] [Related]
16. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
17. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
[TBL] [Abstract][Full Text] [Related]
18. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
Blass E; Ott PA
Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
[TBL] [Abstract][Full Text] [Related]
19. Determinants for Neoantigen Identification.
Garcia-Garijo A; Fajardo CA; Gros A
Front Immunol; 2019; 10():1392. PubMed ID: 31293573
[TBL] [Abstract][Full Text] [Related]
20. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
